ONC - BeiGene, Ltd. (ONC) Q1 2025 Earnings Call Transcript
2025-05-07 14:04:09 ET
BeiGene, Ltd. (ONC)
Q1 2025 Results Conference Call
May 07, 2025 08:00 AM ET
Company Participants
Dan Maller - Head, Investor Relations
John Oyler - Co-Founder, Chairman & Chief Executive Officer
Xiaobin Wu - President & Chief Operating Officer
Matt Shaulis - General Manager, North America
Lai Wang - Global Head, R&D
Aaron Rosenberg - Chief Financial Officer
Conference Call Participants
Andrew Berens - Leerink Partners
Yaron Werber - Cowen and Company
Jessica Fye - JPMorgan
Reni Benjamin - Citizens
Michael Schmidt - Guggenheim Partners
Ziyi Chen - Goldman Sachs
Clara Dong - Jefferies
Gregory Renza - RBC Capital
Sean Laaman - Morgan Stanley
Yigal Nochomovitz - Citigroup
Presentation
Dan Maller
[Abrupt Start]…our Investor Relations website, along with our earnings release. All information in this presentation is as of the date of this presentation, and we undertake no duty to update such information unless required by law.
Now turning to today's call as outlined on Slide 3. John Oyler, our Co-Founder, Chairman and CEO, will provide a business update; Xiaobin Wu, our President and Chief Operating Officer, will provide an update on our global commercial progress; Matt Shaulis, our General Manager of North America, will provide an update on the U.S. commercial performance of BRUKINSA; Lai Wang, our Global Head of R&D, will discuss our R&D and pipeline progress; and Aaron Rosenberg, our CFO will review the first quarter financial results and financial guidance. We will then open the call to your questions. I'll now pass the call over to John. John?
John Oyler
Thank you, Dan, and welcome, everyone, to our Q1 earnings call. Last quarter's call, I spoke about 3 priorities for 2025. The first was solidifying and deepening our hematology franchise leadership. The second was advancing our prolific pipeline of internally developed assets. And the third was driving superior financial performance. I'm excited to share with you how we delivered on these priorities through the first quarter. BeiGene is the only company with an internally discovered and wholly owned portfolio of potentially in-class molecules across all 3 foundational mechanisms in CLL.
We believe our relentless focus on serial innovation and CLL uniquely positions us to address the full scope of unmet patient need across all lines of therapy in subpopulations. BRUKINSA is the best-in-class BTK inhibitor that serves as the backbone of our franchise. In the U.S., BRUKINSA is the leader in new patient starts for both frontline and relapsed refractory CLL and across all of its approved indications. BRUKINSA possesses the broadest label of any BTKi and for the first time, BRUKINSA has surpassed both ibrutinib and acalabrutinib in overall U.S. quarterly revenue and continues to outpace its BTKi competitors in year-over-year growth.
This leadership follows science and the data and reflects BRUKINSA's clear clinical differentiation. BRUKINSA is the only BTKi to exhibit complete and sustained inhibition, and it's the only BTKi to demonstrate superior efficacy and safety in a head-to-head trial against ibrutinib. And anchored by its best-in-class clinical data, BRUKINSA has now treated over 200,000 patients globally.
Sonro, our potentially best-in-class BCL-2 inhibitor continues to advance rapidly through late-stage clinical development. We've completed enrollment in our Phase III CELESTIAL trial of sonro plus zanu in treatment-naive CLL and we've progressed 2 additional Phase III trials as Lai will review....
BeiGene, Ltd. (ONC) Q1 2025 Earnings Call Transcript